- Trials with a EudraCT protocol (329)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
329 result(s) found for: Insulin Resistance.
Displaying page 1 of 17.
EudraCT Number: 2008-001003-38 | Sponsor Protocol Number: RGHT000540 | Start Date*: 2008-08-01 | |||||||||||
Sponsor Name:The Royal Group of Hospitals, Belfast Trust | |||||||||||||
Full Title: A study investigating rimonabant versus placebo in conjunction with a strict low-fat weight reduction diet in overweight and obese subjects: effects on glucose and lipid metabolism and cardiovascul... | |||||||||||||
Medical condition: This study will investigate subjects who are overweight and obese with Body Mass Index >27kg/m2. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-010999-19 | Sponsor Protocol Number: MEC-2009-074 | Start Date*: 2010-07-07 | |||||||||||
Sponsor Name:Erasmus MC - Sophia Children's Hospital | |||||||||||||
Full Title: Protein and Energy Interactions in Critically Ill Children | |||||||||||||
Medical condition: We want to study protein, glucose and lipid metabolism in critically ill septic children admitted to the PICU. As these children often receive insulin because of hyperglycemia due to insulin resist... | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-009278-29 | Sponsor Protocol Number: S51477 | Start Date*: Information not available in EudraCT | ||||||||||||||||||||||||||
Sponsor Name:UZ Leuven | ||||||||||||||||||||||||||||
Full Title: Follow-up studie: Metformin therapie bij kinderen en adolescenten met neurogene of neuromusculaire aandoeningen | ||||||||||||||||||||||||||||
Medical condition: Neuromuscular and neurological diseases, associated with obesity and insulin resistance | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: BE (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-003537-18 | Sponsor Protocol Number: HYDRA-02 | Start Date*: 2023-01-13 | |||||||||||
Sponsor Name:Medizinische Universität Graz | |||||||||||||
Full Title: Assessment of the Tissue Hydraulic Resistance at the Site of Subcutaneous Insulin Infusion and Its Relation to Subcutaneous Insulin Absorption | |||||||||||||
Medical condition: Diabetes Mellitus type 1 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-007748-33 | Sponsor Protocol Number: AIRCo01.12.2008/1 | Start Date*: 2010-04-09 | |||||||||||
Sponsor Name:Foreest Medical School | |||||||||||||
Full Title: Dipeptide Alanyl Glutamine Prevents Postoperative Insulin Resistance in Colon Carcinoma Patients | |||||||||||||
Medical condition: Insulin resistance in colon cancer patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000935-18 | Sponsor Protocol Number: UoL000841 | Start Date*: 2012-06-28 | |||||||||||
Sponsor Name:University of Liverpool [...] | |||||||||||||
Full Title: TAILoR – (TelmisArtan and InsuLin Resistance in HIV): A Dose-Ranging Phase II Randomised Open-Labelled Trial of Telmisartan as a strategy for the Reduction of Insulin Resistance in HIV-Positive Ind... | |||||||||||||
Medical condition: Insulin resistance in HIV-positive patients treated with antiretroviral therapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001562-16 | Sponsor Protocol Number: RGHT000278 | Start Date*: 2006-11-01 | |||||||||||
Sponsor Name:Royal Group of Hospitals Trust | |||||||||||||
Full Title: Studies of insulin action in patients at increased vascular risk. Modulation by antihypertensive and endocrine replacement therapy. | |||||||||||||
Medical condition: Protocol (a): Essential Hypertension Protocol (b): Hypertension in Type 2 Diabetes Protocol (c): Panhypopituitarism | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020875-22 | Sponsor Protocol Number: MetSNS | Start Date*: 2010-08-20 | |||||||||||||||||||||
Sponsor Name:RUNMC | |||||||||||||||||||||||
Full Title: In vivo induction of heme oxygenase-1 (HO-1) in the metabolic syndrome (MetS). Influence of heme arginate (Normosang) infusion on heme oxygenase-1 activity, endothelial dysfunction, insulin resista... | |||||||||||||||||||||||
Medical condition: Subjects suffer from the metabolic syndrome. Effects of study medication on insulin resistance and vascular function will be studied respectively. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-000872-41 | Sponsor Protocol Number: BGP-15-CLIN-IR01 | Start Date*: 2005-04-19 |
Sponsor Name:N-Gene Research & Development Ltd. | ||
Full Title: RANDOMIZED DOUBLE-BLIND, MULTIPLE DOSE, PLACEBO-CONTROLLED STUDY TO DETERMINE THE INSULIN SENSITIZING EFFECT OF BGP-15 IN PATIENTS WITH INSULIN RESISTANCE | ||
Medical condition: The metabolic syndrome is characterized by central obesity, atherogenic dyslipidemia, insulin resistance or glucose intolerance; prothrombotic state; raised blood pressure, proinflammatory state | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: HU (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2013-001791-38 | Sponsor Protocol Number: HYDRA-01 | Start Date*: 2013-06-04 | |||||||||||
Sponsor Name:Medizinische Universität Graz; Universitätsklinik für Innere Medizin; Abteilung für Endokrinologie und Stoffwechsel | |||||||||||||
Full Title: Evaluation of the Hydraulic Tissue Resistance at the Site of Subcutaneous Insulin Infusion and Determination of Its Relationship to Insulin Absorption and Duration of Use of the Infusion Site | |||||||||||||
Medical condition: Diabetes Mellitus type 1 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005311-32 | Sponsor Protocol Number: RHEO-01 | Start Date*: 2016-01-21 | |||||||||||
Sponsor Name:Medizinische Universität Graz; Universitätsklinik fürInnere Medizin; Abteilung für Endokrinologie und Stoffwechsel | |||||||||||||
Full Title: Assessment of the Hydraulic Tissue Resistance at the Site of Subcutaneous Insulin Infusion in Patients with Type 1 Diabetes | |||||||||||||
Medical condition: Diabetes Mellitus type 1 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-002368-27 | Sponsor Protocol Number: VIT C | Start Date*: 2005-07-01 | |||||||||||
Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO" | |||||||||||||
Full Title: EFFECT OF AN ANTI-OXIDANT TREATMENT ON RESISTIN SERUM LEVELS. A RANDOMISED STUDY | |||||||||||||
Medical condition: Data suggesting participation of resistin, a new discovered protein, whose biological significance is still uncertain, in oxidative processes have been sporadically published. One is tempted to spe... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016678-34 | Sponsor Protocol Number: CRO1456 | Start Date*: 2010-04-15 |
Sponsor Name:Imperial College London | ||
Full Title: Exploring the Relationship Between Insulin Resistance and Interferon Resistance: Options to Overcome HCV Non-Response to Pegylated Interferon | ||
Medical condition: HCV infected patient who do not response to Pegylated Interferon. This study is trying to explore the relationship between insulin resistance and Interferon Resistance and the possible rule of Pio... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-023980-17 | Sponsor Protocol Number: Metformin 3.0 | Start Date*: 2011-08-24 |
Sponsor Name:St. Antonius Hospital | ||
Full Title: An efficacy, safety and pharmacokinetic study on the short-term and long-term use of METFORMIN in obese children and adolescents | ||
Medical condition: obese children and adolescents of Caucasian descent with insulin resistance in the age of ≥ 10 and ≤ 16 years at study entry. | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-000197-35 | Sponsor Protocol Number: IR-HP-14-01 | Start Date*: 2015-06-09 | ||||||||||||||||
Sponsor Name:AOU DI BOLOGNA POLICLINICO S.ORSOLA-MALPIGHI | ||||||||||||||||||
Full Title: insulin resistance, obesity and gastrointestinal bacteria | ||||||||||||||||||
Medical condition: Helicobacter pylori infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-001953-24 | Sponsor Protocol Number: WON001 | Start Date*: 2007-07-21 |
Sponsor Name:University of Dundee | ||
Full Title: ''Metformin in Insulin Resistant LV Dysfunction, a double-blind, placebo-controlled trial'' | ||
Medical condition: Patients who has heart failure and found to be insulin resistant (pre-diabetic state). Insulin resistance can be identified using a blood test. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-000810-31 | Sponsor Protocol Number: na | Start Date*: 2016-07-08 |
Sponsor Name:Maastricht University | ||
Full Title: Impact of L-Carnitine infusion on Lipid induced Insulin resistance | ||
Medical condition: Glucose tolerance | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2011-006165-18 | Sponsor Protocol Number: FEN | Start Date*: 2012-06-20 |
Sponsor Name:Academic Medical Center | ||
Full Title: A randomized double blind placebo controlled study on the effects of fenretinide Lym-X-Sorb on insulin sensitivity in obese insulin resistant subjects | ||
Medical condition: Obesity Metabolic syndrome X Insulin resistance Fatty liver | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2022-000743-68 | Sponsor Protocol Number: LDX0122 | Start Date*: 2022-12-13 | |||||||||||
Sponsor Name:DOMPé FARMACEUTICI S.P.A. | |||||||||||||
Full Title: A phase II randomized, placebo-controlled, double-blinded, 2-parallel arm, clinical trial evaluating Ladarixin 400 mg twice a day as adjunctive therapy to improve glycemic control in overweight ins... | |||||||||||||
Medical condition: overweight insulin-resistant patients with type 1 diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-003861-34 | Sponsor Protocol Number: 0/2004 | Start Date*: 2005-06-08 |
Sponsor Name:Department of Nuclear Medicine | ||
Full Title: Influence of the PPAR gamma -agonist Pioglitazone on endothelial function in the peripheral and myocardial vascular territories and on myocardial efficiency in obese subjects | ||
Medical condition: There is an association between insulin resistance and endothelial dysfunction which is thought to be a critical factor in the development of vascular disease and thus an important factor in the de... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
